Recent developments include quarterly earnings reports showing net losses and revenue growth for LOQTORZI, initiation of a Phase 1 clinical trial for a combination therapy, and capital raising activities.

• Coherus Oncology reported a net loss and revenue growth for Q2 2026, with LOQTORZI net revenues of $13.6 million for the quarter [N1].
• The company and Zumutor Therapeutics began a Phase 1 trial of ZM008 and LOQTORZI combination therapy in June 2026 [N2].
• Q1 2026 earnings call and transcript highlighted operational and financial results including net loss and product sales [N3][N4][N5].
• Coherus Oncology reported a net loss and missed revenue estimates for Q4 2025 [N6].
• The company completed a public offering in early 2026, raising net proceeds of $53.6 million [N8].

Coherus Oncology has an approved commercial product, LOQTORZI, generating increasing revenues in the US market. The company is advancing multiple immuno-oncology candidates through clinical trials, including combination therapies, which could expand its product portfolio. Strategic collaborations provide access to promising assets and potential milestone payments. The company maintains liquidity through recent capital raises and has a focused commercial strategy targeting oncology markets.

Coherus Oncology has a limited history of profitability and reported net losses in recent quarters. The company depends on raising additional funds to support operations and product development. Manufacturing risks, including transitioning biomanufacturing processes, and reliance on third parties for clinical studies and supply pose operational challenges. Regulatory scrutiny and competition from other immuno-oncology biologics may limit market penetration. Adverse side effects or regulatory delays could impact product approvals and commercialization.

Coherus Oncology's moat is based on its approved next-generation PD-1 inhibitor, LOQTORZI, and its collaboration agreements, including with Junshi Biosciences, which provide exclusive rights and options to additional immuno-oncology candidates. The company's integrated commercial capabilities and ongoing clinical development pipeline contribute to its competitive positioning. However, the oncology market is highly competitive with rapid technological change and significant regulatory hurdles, which may limit the company's ability to establish a durable competitive advantage.

• Limited Profitability History: The company has a limited history of profitability and may not achieve or maintain profitability in the future.
• Dependence on Additional Funding: Coherus relies on the ability to raise funds to support product development and commercialization; failure to obtain capital on acceptable terms may limit operations.
• Regulatory and Manufacturing Risks: The company faces significant regulatory scrutiny and manufacturing risks, including compliance with cGMP and transitioning biomanufacturing processes, which could increase costs or delay supply.
• Competition and Market Acceptance: LOQTORZI and product candidates face significant competition from other immuno-oncology biologics; market acceptance depends on clinical efficacy, safety, pricing, and reimbursement.
• Reliance on Third Parties: Coherus depends on third parties for clinical studies and manufacturing; failure by these parties to meet obligations or regulatory requirements could harm the business.
• Intellectual Property Risks: Claims of intellectual property infringement or failure to protect proprietary rights could delay or prevent development and commercialization.
• Adverse Events and Side Effects: Undesirable side effects of products could delay or prevent regulatory approval or limit commercial potential.
• Geopolitical Risks: Ongoing conflicts such as the war in Ukraine and Middle East tensions may exacerbate operational risks.

• Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company focused on developing and commercializing human pharmaceutical products in the United States.
• The company has one approved and marketed product, LOQTORZI, a next-generation programmed death receptor-1 (PD-1) inhibitor launched in January 2024.
• Coherus Oncology has multiple product candidates in development, including immuno-oncology biologics such as tagmokitug and casdozokitug, and is conducting clinical trials including a Phase 1 trial of ZM008 and LOQTORZI combination with Zumutor Therapeutics.
• The company operates primarily in the United States, with all net product revenue generated domestically.
• Net revenues for LOQTORZI were $13.6 million for the three months ended June 30, 2026, and $25.4 million for the six months ended June 30, 2026.
• Major customers for product sales include McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc., accounting for significant portions of gross product revenues.
• Coherus Oncology's financials as of June 30, 2026, include cash and cash equivalents of approximately $82.9 million, short-term investments of $22.4 million, total current assets of $133.8 million, and current liabilities of $75.5 million, resulting in a current ratio of 1.77 and a cash ratio of 1.39.
• The company reported a net loss from continuing operations of $33.3 million for the three months ended June 30, 2026, and a net loss of $20.6 million for the six months ended June 30, 2026.
• Coherus Oncology completed a public offering in early 2026, issuing 32.9 million shares and raising net proceeds of $53.6 million.
• The company is party to a sales agreement allowing at-the-market offerings with approximately $64.9 million of common stock remaining available for sale as of June 30, 2026.
• Coherus Oncology is subject to significant regulatory scrutiny, including compliance with cGMP regulations for manufacturing and FDA oversight for product approvals and clinical trials.
• The company faces risks including limited history of profitability, dependence on raising additional funds, competition from other immuno-oncology biologics, regulatory risks, manufacturing risks including transitioning biomanufacturing processes, and potential adverse side effects of products.
• Coherus Oncology relies on third parties for nonclinical and clinical studies and manufacturing, which introduces risks related to compliance, timelines, and supply.
• The company has an accumulated deficit of approximately $1.44 billion as of June 30, 2026.
• Coherus Oncology's product and product candidates face competition and rapid technological change, with market acceptance dependent on clinical efficacy, safety, pricing, and reimbursement coverage.
• The company has collaboration agreements, including with Junshi Biosciences for co-development and commercialization of toripalimab (LOQTORZI) in the US and Canada, involving upfront payments, royalties, and milestone payments.
• The company reported losses from operations and net losses in recent quarters, with operating expenses including cost of goods sold, research and development, and selling, general and administrative expenses.
• The company has disclosed risks related to intellectual property, regulatory approval uncertainties, and geopolitical risks such as the war in Ukraine and conflicts in the Middle East.
• Coherus Oncology's chief executive officer manages the company as a single reportable segment, with operating decisions based on net income (loss), revenues, cash on-hand, and cash flows.